|
1
|
Kilfoy BA, Zheng T, Holford TR, Han X,
Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, et al:
International patterns and trends in thyroid cancer incidence,
1973–2002. Cancer Causes Control. 20:525–531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen AY, Jemal A and Ward EM: Increasing
incidence of differentiated thyroid cancer in the United States,
1988–2005. Cancer. 115:3801–3807. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sherman SI: Thyroid carcinoma. Lancet.
361:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xing M, Haugen BR and Schlumberger M:
Progress in molecular-based management of differentiated thyroid
cancer. Lancet. 381:1058–1069. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA,
Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in
thyroid cancer: Genetic evidence for constitutive activation of the
RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
|
|
6
|
Cohen Y, Xing M, Mambo E, Guo Z, Wu G,
Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF
mutation in papillary thyroid carcinoma. J Natl Cancer Inst.
95:625–627. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ciampi R, Knauf JA, Kerler R, Gandhi M,
Zhu Z, Nikiforova MN, Rabes HM, Fagin JA and Nikiforov YE:
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway
activation in thyroid cancer. J Clin Invest. 115:94–101. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wreesmann VB, Sieczka EM, Socci ND, Hezel
M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky
M, et al: Genome-wide profiling of papillary thyroid cancer
identifies MUC1 as an independent prognostic marker. Cancer Res.
64:3780–3789. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moon S, Song YS, Kim YA, Lim JA, Cho SW,
Moon JH, Hahn S, Park DJ and Park YJ: Effects of coexistent
BRAFV600E and TERT promoter mutations on poor clinical
outcomes in papillary thyroid cancer: A meta-analysis. Thyroid.
27:651–660. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee JJ, Wang TY, Liu CL, Chien MN, Chen
MJ, Hsu YC, Leung CH and Cheng SP: Dipeptidyl peptidase IV as a
prognostic marker and therapeutic target in papillary thyroid
carcinoma. J Clin Endocrinol Metab. 102:2930–2940. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chowdhury S, Veyhl J, Jessa F, Polyakova
O, Alenzi A, MacMillan C, Ralhan R and Walfish PG: Programmed
death-ligand 1 overexpression is a prognostic marker for aggressive
papillary thyroid cancer and its variants. Oncotarget.
7:32318–32328. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Samaan NA, Schultz PN, Hickey RC, Goepfert
H, Haynie TP, Johnston DA and Ordonez NG: The results of various
modalities of treatment of well differentiated thyroid carcinomas:
A retrospective review of 1599 patients. J Clin Endocrinol Metab.
75:714–720. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schlumberger MJ: Papillary and follicular
thyroid carcinoma. N Engl J Med. 338:297–306. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Durante C, Haddy N, Baudin E, Leboulleux
S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De
Vathaire F, et al: Long-term outcome of 444 patients with distant
metastases from papillary and follicular thyroid carcinoma:
Benefits and limits of radioiodine therapy. J Clin Endocrinol
Metab. 91:2892–2899. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haugen BR: 2015 American Thyroid
Association management guidelines for adult patients with thyroid
nodules and differentiated thyroid cancer: What is new and what has
changed? Cancer. 123:372–381. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
O'Neill CJ, Oucharek J, Learoyd D and
Sidhu SB: Standard and emerging therapies for metastatic
differentiated thyroid cancer. Oncologist. 15:146–156. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mazzaferri EL and Kloos RT: Clinical
review 128: Current approaches to primary therapy for papillary and
follicular thyroid cancer. J Clin Endocrinol Metab. 86:1447–1463.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mazzaferri EL and Jhiang SM:
Differentiated thyroid cancer long-term impact of initial therapy.
Trans Am Clin Climatol Assoc. 106(151–168): discussion 168–170.
1995.PubMed/NCBI
|
|
19
|
Visone R, Russo L, Pallante P, De Martino
I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM and
Fusco A: MicroRNAs (miR)-221 and miR-222, both overexpressed in
human thyroid papillary carcinomas, regulate p27Kip1 protein levels
and cell cycle. Endocr Relat Cancer. 14:791–798. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mancikova V, Castelblanco E, Pineiro-Yanez
E, Perales-Paton J, de Cubas AA, Inglada-Perez L, Matias-Guiu X,
Capel I, Bella M, Lerma E, et al: MicroRNA deep-sequencing reveals
master regulators of follicular and papillary thyroid tumors. Mod
Pathol. 28:748–757. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cancer Genome Atlas Research Network:
Integrated genomic characterization of papillary thyroid carcinoma.
Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao M, Wang KJ, Tan Z, Zheng CM, Liang Z
and Zhao JQ: Identification of potential therapeutic targets for
papillary thyroid carcinoma by bioinformatics analysis. Oncol Lett.
11:51–58. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Geraldo MV and Kimura ET: Integrated
analysis of thyroid cancer public datasets reveals role of
post-transcriptional regulation on tumor progression by targeting
of immune system mediators. PLoS One. 10:e01417262015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dweep H and Gretz N: miRWalk2.0: A
comprehensive atlas of microRNA-target interactions. Nat Methods.
12:6972015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The microRNA.org resource: Targets and expression.
Nucleic Acids Res. 36:D149–D153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar :
|
|
27
|
Kanehisa M, Sato Y, Kawashima M, Furumichi
M and Tanabe M: KEGG as a reference resource for gene and protein
annotation. Nucleic Acids Res. 44:D457–D462. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The gene
ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
da Huang W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using david
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for rna-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate-a practical and powerful approach to
multiple testing. J R Stat Soc Ser B-Methodol. 57:289–300.
1995.
|
|
32
|
Le Pennec S, Konopka T, Gacquer D,
Fimereli D, Tarabichi M, Tomas G, Savagner F, Decaussin-Petrucci M,
Tresallet C, Andry G, et al: Intratumor heterogeneity and clonal
evolution in an aggressive papillary thyroid cancer and matched
metastases. Endocr Relat Cancer. 22:205–216. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Saiselet M, Gacquer D, Spinette A, Craciun
L, Decaussin-Petrucci M, Andry G, Detours V and Maenhaut C: New
global analysis of the microRNA transcriptome of primary tumors and
lymph node metastases of papillary thyroid cancer. BMC Genomics.
16:8282015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin RY: Thyroid cancer stem cells. Nat Rev
Endocrinol. 7:609–616. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Takano T, Miyauchi A, Yokozawa T,
Matsuzuka F, Maeda I, Kuma K and Amino N: Preoperative diagnosis of
thyroid papillary and anaplastic carcinomas by real-time
quantitative reverse transcription-polymerase chain reaction of
oncofetal fibronectin messenger RNA. Cancer Res. 59:4542–4545.
1999.PubMed/NCBI
|
|
36
|
Are C and Shaha AR: Anaplastic thyroid
carcinoma: Biology, pathogenesis, prognostic factors, and treatment
approaches. Ann Surg Oncol. 13:453–464. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hou Z, Meyer S, Propson NE, Nie J, Jiang
P, Stewart R and Thomson JA: Characterization and target
identification of a DNA aptamer that labels pluripotent stem cells.
Cell Res. 25:390–393. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rao SR, Snaith AE, Marino D, Cheng X, Lwin
ST, Orriss IR, Hamdy FC and Edwards CM: Tumour-derived alkaline
phosphatase regulates tumour growth, epithelial plasticity and
disease-free survival in metastatic prostate cancer. Br J Cancer.
116:227–236. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Iwadate Y, Suganami A, Tamura Y, Matsutani
T, Hirono S, Shinozaki N, Hiwasa T, Takiguchi M and Saeki N: The
pluripotent stem-cell marker alkaline phosphatase is highly
expressed in refractory glioblastoma with DNA hypomethylation.
Neurosurgery. 80:248–256. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vosa U, Vooder T, Kolde R, Vilo J,
Metspalu A and Annilo T: Meta-analysis of microRNA expression in
lung cancer. Int J Cancer. 132:2884–2893. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tan X, Qin W, Zhang L, Hang J, Li B, Zhang
C, Wan J, Zhou F, Shao K, Sun Y, et al: A 5-microRNA signature for
lung squamous cell carcinoma diagnosis and hsa-miR-31 for
prognosis. Clin Cancer Res. 17:6802–6811. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang X, Zhang T, Yang K, Zhang M and Wang
K: miR-486-5p suppresses prostate cancer metastasis by targeting
Snail and regulating epithelial-mesenchymal transition. Onco
Targets Ther. 9:6909–6914. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Burton A: Regulation of RANKL might reduce
bone metastases. Lancet Oncol. 7:3672006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Torregrossa L, Giannini R, Borrelli N,
Sensi E, Melillo RM, Leocata P, Materazzi G, Miccoli P, Santoro M
and Basolo F: Cxcr4 expression correlates with the degree of tumor
infiltration and braf status in papillary thyroid carcinomas. Mod
Pathol. 25:46–55. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ponnusamy MP, Lakshmanan I, Jain M, Das S,
Chakraborty S, Dey P and Batra SK: Muc4 mucin-induced epithelial to
mesenchymal transition: A novel mechanism for metastasis of human
ovarian cancer cells. Oncogene. 29:5741–5754. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Singh AP, Moniaux N, Chauhan SC, Meza JL
and Batra SK: Inhibition of muc4 expression suppresses pancreatic
tumor cell growth and metastasis. Cancer Res. 64:622–630. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rowson-Hodel AR, Wald JH, Hatakeyama J,
O'Neal WK, Stonebraker JR, VanderVorst K, Saldana MJ, Borowsky AD,
Sweeney C and Carraway KL III: Membrane mucin muc4 promotes blood
cell association with tumor cells and mediates efficient metastasis
in a mouse model of breast cancer. Oncogene. 37:197–207. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li W, Liu C, Zhao C, Zhai L and Lv S:
Downregulation of β3 integrin by miR-30a-5p modulates cell adhesion
and invasion by interrupting Erk/Ets-1 network in triple-negative
breast cancer. Int J Oncol. 48:1155–1164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wei W, Yang Y, Cai J, Cui K, Li RX, Wang
H, Shang X and Wei D: miR-30a-5p suppresses tumor metastasis of
human colorectal cancer by targeting ITGB3. Cell Physiol Biochem.
39:1165–1176. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chung YH, Li SC, Kao YH, Luo HL, Cheng YT,
Lin PR, Tai MH and Chiang PH: miR-30a-5p inhibits
epithelial-to-mesenchymal transition and upregulates expression of
tight junction protein claudin-5 in human upper tract urothelial
carcinoma cells. Int J Mol Sci. 18:E18262017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ruggero D and Pandolfi PP: Does the
ribosome translate cancer? Nat Rev Cancer. 3:179–192. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ma ZF and Skeaff SA: Thyroglobulin as a
biomarker of iodine deficiency: A review. Thyroid. 24:1195–1209.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Vermeulen L, Sprick MR, Kemper K, Stassi G
and Medema JP: Cancer stem cells-old concepts, new insights. Cell
Death Differ. 15:947–958. 2008. View Article : Google Scholar : PubMed/NCBI
|
